Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
185
resultados
Última actualización
08/12/2025 [07:22:00]
Resultados 75 a 100 de 185
Resumen de: CN120559221A
The invention discloses application of Gli1 + interstitial cells or SMOC2 protein thereof in diagnosis, treatment and prognosis evaluation of Crohn disease intestinal stenosis. The invention provides application of Gli1 + interstitial cells and SMOC2 protein as targets in preparation of a diagnostic kit or a therapeutic drug for Crohn disease fibrostenosis, and further provides the diagnostic kit for Crohn disease fibrostenosis and the therapeutic drug for Crohn disease fibrostenosis. Meanwhile, the invention further provides application of the reagent for detecting the expression quantity of the SMOC2 in preparation of the kit for evaluating postoperative recurrence of the Crohn disease fibrostenosis and the corresponding kit for evaluating postoperative recurrence of the Crohn disease fibrostenosis. The invention discusses the effect of the Gli1 + interstitial cells in the attack of intestinal fibrostenosis, evaluates the potential of the Gli1 + interstitial cells as a diagnosis and treatment target, and provides a new thought for the treatment of Crohn disease intestinal stenosis.
Resumen de: CN120549942A
According to the application, the application of the taurocholic acid (TCA) in the medicine for preventing and treating the colitis injury is found and proved, the clinical effect is remarkable, the TCA with a proper concentration can promote the growth of Caco-2 cells and can relieve inflammation caused by LPS, but the TCA with a high concentration can inhibit the growth of the Caco-2 cells. Through intragastric administration of TCA, mouse colitis induced by escherichia coli can be relieved, TCA with a proper concentration can treat colitis, and through in-vitro and in-vivo dual verification, the optimal concentration of TCA in the aspect of treating colitis and the treatment effect of TCA on colitis caused by pathogenic escherichia coli are determined. Theoretical support is provided for medicine development of TCA in the aspect of treating intestinal inflammation, and the TCA is worthy of being widely popularized and used clinically.
Resumen de: WO2025177282A1
A system for predicting a response to nutritional therapy for treating Crohn's Disease (CD), including a computer with a processor and memory, a machine learning module, wherein the machine learning module is programed to train a model by accepting a training data set comprising multiomics data of subjects with Crohn's disease that were treated by exclusive enteral nutrition (EEN) and a determination if each subject was a responder that successfully responded to the treatment or was a non-responder that unsuccessfully responded to the treatment, and wherein the machine learning module uses the trained model to accept multiomics data of a patient and predict if the patient is a responder or a non-responder.
Resumen de: WO2025179106A1
A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.
Resumen de: WO2025176879A1
The present invention relates to methods of immunoassay for detecting or monitoring inflammatory bowel disease or a severity thereof in a patient. In certain embodiments, the inflammatory bowel disease may be ulcerative colitis.
Resumen de: WO2025176817A1
The present invention relates to diagnostic and prognostic methods and their use in diagnosing or predicting disease progression in a subject with Ulcerative Colitis (UC). More particularly, the present invention relates to a gene expression signature and the use thereof in determining the likelihood of progression of Ulcerative Colitis in a subject, as well as compositions for the detection thereof. The invention also extends to the use of biomarkers as targets to improve the treatment of Ulcerative Colitis in patients.
Resumen de: US2025271429A1
A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.
Resumen de: EP4607197A1
Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin αvβ6 in a specimen.
Resumen de: AU2023364180A1
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of
Resumen de: EP4606910A1
The present invention relates to diagnostic and prognostic methods and their use in diagnosing or predicting disease progression in a subject with Ulcerative Colitis (UC). More particularly, the present invention relates to a gene expression signature and the use thereof in determining the likelihood of progression of Ulcerative Colitis in a subject, as well as compositions for the detection thereof. The invention also extends to the use of biomarkers as targets to improve the treatment of Ulcerative Colitis in patients.
Resumen de: CN120536298A
The invention belongs to the technical field of microorganisms, and discloses lactobacillus fermentum (L.f) LFSJ001 and application of the lactobacillus fermentum (L.f) LFSJ001 in preparation of a product for preventing or treating ulcerative colitis. The lactobacillus fermentum LFSJ001 is subjected to autonomous separation and identification. According to the application disclosed by the invention, a mouse colitis model is constructed by using DSS, and it is found that combined treatment of lactobacillus fermentum LFSJ001 and mesalazine (5-ASA) can enhance improvement of 5-ASA on colitis symptoms, including a plurality of indexes such as a disease activity index, a colon injury index and a spleen index. Therefore, the lactobacillus fermentum LFSJ001 can be used as a combined medicine of the 5-ASA, the medicine effect of the 5-ASA is enhanced, the occurrence and development of the ulcerative colitis are inhibited, the intestinal barrier is improved, and a new diagnosis and treatment direction and strategy are provided for prevention and treatment of the ulcerative colitis.
Resumen de: CN120536347A
The invention discloses a preparation method of an intestinal organ inflammation model based on inflammatory factors, and belongs to the technical field of biomedicine. The invention provides an innovative in-vitro culture method based on intestinal organs, and aims to simulate inflammatory response in inflammatory bowel disease (IBD) and influence of the inflammatory response on intestinal epithelium and stem cells. Specific inflammatory factors IL-22, IFN-gamma and TNF-alpha are introduced into an organoid culture system, an inflammatory environment related to IBD is successfully induced, and a key feature of IBD is observed: expression of a fetal-like intestine stem cell marker gene Sca-1 is remarkably increased. The model fully simulates the repair mechanism of the intestinal tract in inflammatory response. The invention discloses key effects of different inflammatory factors on intestinal epithelium functions and fetal-like intestine stem cells in a repair process, and provides a unique in-vitro platform for deeply researching a repair mechanism. The invention provides a novel in-vitro experimental platform for mechanism research, diagnosis, personalized treatment and drug screening of the inflammatory bowel disease.
Resumen de: JP2025124594A
To provide novel therapies for treating or ameliorating inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, as well as for treating other autoimmune conditions.SOLUTION: The present invention relates to antibodies that specifically bind to one or both of IL27RA and gp130. The present invention further relates to bispecific antibodies that specifically bind to IL27RA and gp130. The present invention also relates to related molecules, e.g., nucleic acids encoding such antibodies or bispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and bispecific antibodies, and their use in diagnostic and therapeutic agents.SELECTED DRAWING: Figure 1
Resumen de: CN120519578A
The invention provides an application of APOL1 in diagnosis of neonatal necrotizing enterocolitis. Research finds that compared with a control child patient, the APOL1 gene and protein expression level in NEC child patients are remarkably improved for the first time, ROC curve analysis results show that when APOL1 is used for NEC diagnosis, AUC is 0.86, and diagnosis accuracy is high. Therefore, the APOL1 can be used as a specific diagnostic marker of the NEC for assisting clinical diagnosis of the NEC. Furthermore, when the APOL1 is combined with C reactive protein, lymphocyte count (LYM) or hemoglobin level to be used for NEC diagnosis, AUC can be further improved to 0.91-0.94, and the diagnosis accuracy is further improved. The invention provides a novel specific biomarker for diagnosis of NEC, and has important clinical value for early diagnosis and early treatment of NEC.
Resumen de: AU2024230939A1
Described herein are methods of reducing CD3-dependent T cell signaling in a subject in need thereof. Also described are method of increasing T-regulatory (Treg) cells, or decreasing T-helper 17 (Th17) cells. These methods involve administering butyrophilin A2 (BTN2A2), a BTN2A2 fragment thereof, a BTN2A2-related isoform, or a BTN2A2-related isoform fragment, or a conjugate or fusion polypeptide comprising any of the foregoing to the subject. These methods are beneficial for patients with autoimmune disorders and inflammatory disorders such as allergy, asthma, glomerulonephritis, inflammatory bowel disease, rheumatoid arthritis, an autoimmune or inflammatory neurological disease, antibody mediated transplant rejection, infantile cholestasis, haemophagocytic lymphohistiocytosis, erythrocytic haemophagocytosis, malnutrition, systemic lupus erythematosus (lupus), psoriasis, myasthenia gravis or HIV. Further described are fusion proteins having BTN2A2 and an Fc domain.
Resumen de: US2025262251A1
Provided are methods for treating an individual who has inflammatory bowel diseases (IBD and) spondyloarthritis by selecting the individual based on a determination that that the gastrointestinal system of the individual comprises a microbiome lacking bacteria that provide functional folate trap, and administering to the individual sulfasalazine and bacteria that include a functional folate trap to thereby treat the IBD.
Resumen de: WO2025172923A1
The present disclosure relates to a system (102) and a method (300) for personalized health management to provide recommendations for a user diagnosed with IBS and related symptoms. The method (300) includes receiving (302) user datasets, determining (304) a current IBS symptom score, and computing (306) a target IBS symptom score. A personalized plan is recommended, initiating (308) a gut cleansing phase to arrive at a first IBS symptom score and assessing (310) and revising the plan for a reintroduction phase to determine a second IBS symptom score. Further, assessing (312) identifies symptom triggers, refining the plan to arrive at a third IBS symptom score. At a sustenance phase, assessing (314) determines long-term impacts and revises the plan to maintain the target IBS symptom score. Therefore, the present disclosure provides a data-driven, adaptive system for dynamic IBS management, ensuring sustained improvement and symptom control.
Resumen de: JP2025120083A
To provide a pharmaceutical for treating, preventing relapse, or maintaining remission of inflammatory bowel disease.SOLUTION: The present invention provides a pharmaceutical for treating, preventing relapse, or maintaining remission of inflammatory bowel disease including tryptophanyl tRNA synthetase-like protein as an active component.SELECTED DRAWING: None
Resumen de: CN120496800A
The invention relates to the technical field of disease diagnosis, in particular to an inflammatory bowel disease pathological slice diagnosis method based on a link algorithm, which comprises the following steps: S1, acquiring an inflammatory bowel disease pathological slice; s2, creating a link algorithm; s3, training the link algorithm in the S2 by using the pathological slice of the inflammatory bowel disease obtained in the S1 to obtain an optimal link algorithm; and S4, inputting pathological slices of the inflammatory bowel disease into the optimal link algorithm in the S3, so as to output diagnosis results of the pathological slices of the inflammatory bowel disease, and enabling the diagnosis results of the plurality of pathological slices of the inflammatory bowel disease to form a report to be exported. According to the method, the link algorithm is established, and the microscopic features of a large number of samples are counted, so that a doctor is assisted in finding potential biomarkers and pathological typing rules of the inflammatory bowel disease, objective quantitative indexes can be provided, subjective deviation of manual interpretation can be reduced, and the consistency of ulcerative colitis diagnosis results can be improved.
Resumen de: WO2025171261A1
Compounds are described herein for the detection of the activity of an enzyme. The compounds include a recognition domain/substrate structured to interact with the enzyme, a reporter molecule, and a linking group forming a covalent bond between the recognition domain and reporter molecule. Upon interaction of the recognition domain with the enzyme, the covalent bond is destroyed, rendering reporter molecule detectable by a chemical detection device. Methods of detecting enzymatic activity of a plurality of enzymes are also described herein. Such methods include reacting a compound (having a recognition domain/substrate structured to interact with the enzyme, a reporter molecule, and a linking group forming a covalent bond between the recognition domain and reporter molecule) with an enzyme, and identifying detectable reporter molecules with a chemical detection device.
Resumen de: AU2024224464A1
The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/or diagnostic use in a subgroup of patients having ulcerative colitis.
Resumen de: US2025258170A1
A protein comprising an amino acid sequence according to SEQ ID NO: 1, wherein the amino acid in position 4 of SEQ ID NO: 1 is selected from the group consisting of N, S, R, T and I, preferably consisting of N, S and R and wherein the amino acid in position 5 of SEQ ID NO: 1 is selected from the group consisting of R, V, L, F, M, I, H, S, T, A, P and G, with the proviso that the amino acid sequence is not SEQ ID NO: 24.
Resumen de: US2025255558A1
Systems and methods are disclosed for diagnosis, risk assessment, and/or virtual treatment assessment of visceral ischemia and related disorders. One method includes receiving a patient-specific anatomic model of a patient's visceral vasculature, including visceral vasculature of the patient's visceral organs and bowel; determining a location in the patient-specific anatomic model of the patient's visceral vasculature; determining, for the location in the patient-specific anatomic model, a blood flow characteristic of blood flow through the location in the patient-specific anatomic model of the patient's visceral vasculature; determining a tissue region of the patient's bowel proximate the location in the patient-specific anatomic model of the patient's visceral vasculature; and generating an assessment of blood supply adequacy to the tissue region of the patient's bowel based on the determined blood flow characteristic and an expected blood flow characteristic associated with the tissue region of the patient's bowel.
Resumen de: MX2020002643A
The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a truncated human Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) protein. The disclosure also provides isolated and recombinant human SIGIRR protein variants that comprise a truncation at a position corresponding to position 215. The truncation, and the nucleic acid molecules encoding this change, associate with early-onset inflammatory bowel disease (EO-IBD). The disclosure also provides methods for determining whether a subject has or has a risk of developing EO-IBD, based on the identification of such alterations in the nucleic acid molecules encoding SIGIRR.
Nº publicación: CN120452749A 08/08/2025
Solicitante:
AFFILIATED HOSPITAL OF JIANGNAN UNIV
\u6C5F\u5357\u5927\u5B66\u9644\u5C5E\u533B\u9662
Resumen de: CN120452749A
The invention relates to the field of ulcerative colitis, and discloses a multi-parameter monitoring system for evaluating the intestinal barrier function of ulcerative colitis, which is used for realizing the goal of automatically adjusting a treatment scheme according to a monitoring result by constructing a closed-loop feedback treatment system. According to the invention, by designing the nanoprobe of which the surface is modified with a specific binding element and combining with a swallowing capsule endoscopy, real-time imaging and molecular level dynamic tracking of the intestinal barrier are realized, genetically engineered bacteria are constructed to quantify intestinal permeability abnormality and local inflammation level, and an intestinal barrier function damage score and a disease progress prediction result are output; individual monitoring is achieved through transfer learning, ultrasonic elastography, optical coherence tomography, wearable equipment for measuring intestinal electric field impedance spectroscopy and other technologies are adopted, an intestinal wall mechanics-electrophysiology composite parameter set is obtained, and the evaluation accuracy is improved.
BOPI
Sede Electrónica
